FDA Approves First Drug for Neurological Symptoms of Type 3 Gaucher Disease
Amara Diallo · Science Communicator
November 19, 2026 · 1 min read
The FDA has approved Infilbray (venglustat) tablets for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and children weighing at least 15 kg, according to an FDA press announcement. This marks the first approved therapy specifically targeting the brain related symptoms of this rare inherited condition.
GD3 occurs when the body cannot properly break down fatty molecules called glucosphingolipids due to a faulty enzyme. Unlike Type 1 Gaucher disease, GD3 also affects the brain, causing progressive problems with balance, coordination, speech, memory, and thinking. Infilbray is a glucosylceramide synthase inhibitor that crosses the blood brain barrier to reduce buildup of these harmful substances, including within the brain.
The approval rests on a randomized, double blind, multicenter trial of 43 patients aged 12 and older with GD3 who had already reached systemic stabilization on enzyme replacement therapy. Participants took oral Infilbray daily or continued intravenous enzyme replacement every two weeks for 52 weeks. Those on Infilbray showed improvement on a combined measure of ataxia and cognitive function compared to the enzyme replacement group.
Reported side effects include gastrointestinal symptoms and mood changes, with serious psychiatric risks such as suicidal ideation noted in labeling. Animal studies flagged possible effects on vision in younger patients and on fetal development. The drug received Orphan Drug designation and Priority Review before this approval to Genzyme, a Sanofi company.
This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.
Ready to explore peptides?
Browse every compound profile or work out your dose with the reconstitution calculator.


